Biorem Reports Second Quarter Results with 77% Increase in Year over Year Revenue and Record Order Backlog
FINANCIAL HIGHLIGHTS:
in Canadian dollars, '000's except earnings per share |
|
|||
|
Three-months ended |
Six -months ended |
||
|
|
|
||
|
2024 |
2023 |
2024 |
2023 |
|
|
|
|
|
Revenue |
7,300 |
4,280 |
13,218 |
7,449 |
Gross profit |
1,657 |
954 |
3,437 |
1,070 |
Operating expenses |
1,145 |
1,018 |
2,409 |
1,824 |
Ebitda* |
555 |
- |
1,177 |
(161) |
Net earnings (loss) |
340 |
(96) |
681 |
(650) |
EPS - basic |
0.021 |
(0.006) |
0.043 |
(0.042) |
EPS - fully diluted |
0.018 |
(0.006) |
0.037 |
(0.042) |
* Earnings before interest, taxes and amortizaton, a non IFRS financial measure |
During the quarter the Company booked
The Company expects this record backlog to support strong revenues and earnings in the second half of the year.
"Our strategic initiatives gathered momentum in 2024" said
"There continues to be strong underlying demand for our full range of products and services, continued
Gross profit for the quarter was
The Company had net earnings for the quarter of
Cash on hand at
About
SOURCE